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Abstract
Context: A number of PD-1/PD-L1 inhibitors have recently been approved for use
in patients with locally advanced or metastatic urothelial carcinoma (UC) on the
basis of results from several clinical trials.
Objective: To review the evidence from these trials and considerwhat itmeans for the
use of these drugs in ﬁrst-line and post-platinum settings in real-life clinical practice.
Evidence acquisition: PubMedwas searched for full reports of clinical trials of single-
agent PD-1/PD-L1 inhibitors in advanced UC. Twelve publications were included.
Evidence synthesis: Responses to PD-1/PD-L1 inhibitors appear to be durable but
are only achieved in 17–26% of patients. These drugs offer different toxicity and
efﬁcacy proﬁles to standard chemotherapy regimens. This should be considered
when choosing a treatment strategy for each patient.
Conclusions: PD-1/PD-L1 inhibitors represent a major step forward in the man-
agement of advanced UC, although several questions remain regarding their
optimal use in routine clinical practice. A validated predictive biomarker of
response is yet to be deﬁned, and this is perhaps the most signiﬁcant unmet need
for currently available drugs.
Patient summary: We reviewed the results from clinical trials that investigated how
well certain types of anticancer drugs called PD-1/PD-L1 inhibitors worked in patients
with bladder cancer.We found thatmore research is required to identify (1) the factors
that might predict which patients with bladder cancer will respond to PD-1/PD-L1
inhibitors and (2) the optimum duration of treatment with these drugs.
© 2018 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).* Corresponding author. Institute of Translational & Stratified Medicine, Plymouth University,
Peninsula Schools of Medicine and Dentistry, Davy Road, Plymouth Science Park, Plymouth PL6
8BX, UK. Tel.: +44 1752 764260.
ssain@plymouth.ac.uk (S.A. Hussain).E-mail address: syed.huhttps://doi.org/10.1016/j.euo.2018.05.011
2588-9311/© 2018 The Author(s). Published by Elsevier B.V. on behalf of Eur
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncopean Association of Urology. This is an open access article
-nd/4.0/).
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Immunotherapy is not a novel concept in the treatment of
urothelial carcinoma (UC). For decades, intravesical instilla-
tion of the attenuated mycobacterium bacillus Calmette-
Guérin has been used to prevent disease recurrence or
progression in non–muscle-invasive bladder cancer follow-
ing transurethral resection of the tumour [1]. Now an
exciting and rapidly evolvingmodern era of immunotherapy
has begun in the advanced (locally advanced or metastatic)
UC settingwith the approval of several monoclonal antibody
treatments. The mechanism underlying the antitumour
activity of these drugs is inhibition of immune checkpoints,
such as the PD-1/PD-L1 pathway (Fig. 1), and they offer new
treatment possibilities for patientswho have historically had
few options available to them.
The standard first-line treatment of advanced UC
remains cisplatin-based chemotherapy, such as methotrex-
ate, vinblastine, doxorubicin and cisplatin (MVAC), or
gemcitabine–cisplatin (GC) [2]. These treatments have
confirmed activity in bladder cancer, but are associated
with clinically significant toxicities, including myelosup-
pression, ototoxicity, neurotoxicity, and nephrotoxicity [3–
5]. In a phase 3 randomised trial comparing these regimens,
objective response rates (ORRs) were comparable in the GC
and MVAC groups (49.4% vs 45.7%, respectively), with
approximately 12% of patients in each group achieving a
complete response (CR) [5]. Median overall survival (OS)
was 14.0 and 15.2 mo, respectively, and median progres-
sion-free survival (PFS) was approximately 8 mo in each
treatment arm [6]. Frequent thrombocytopenia and neu-
tropenia were reported for both treatments [5]. Common
grade 3/4 nonhaematological toxicities included nausea,
vomiting, alopecia, infection, and mucositis [5]. Of the two
regimens, GC was associated with lower rates of toxicity-
related mortality, neutropenic sepsis, and grade 3/4
mucositis, making it the preferred first-line treatment
[5]. Most UC patients who respond to first-line cisplatin-
based chemotherapy are likely to experience disease
progression within a disappointingly short period of time
[7]. Until recently, the only treatment option approved for
patients failing first-line chemotherapy was vinflunine (in
Europe only), which was associated with a modest
improvement in PFS versus best supportive care alone
[8]. Other chemotherapy regimens have shown activity in
patients with UC who have progressed on platinum-based
chemotherapy, but these have not been tested in random-
ised phase 3 trials [9], resulting in a lack of consensus on the
standard of care in this setting.
UC is a disease that mostly affects older people, who
often have pre-existing comorbidities and/or renal im-
pairment. Many of these patients are considered “unfit for
cisplatin-based treatment” [10] and, until now, would
commonly be offered carboplatin-based chemotherapy,
such as gemcitabine–carboplatin (GemCarbo) or metho-
trexate, carboplatin, and vinblastine (M-CAVI). In the EORTC
30986 trial that compared these two regimens in cisplatin-
ineligible patients, the ORRwas higherwith GemCarbo than
withM-CAVI (41.2% vs 30.3%), but median OS (9.3 vs 8.1mo)and PFS (5.8 vs 4.2 mo) were similar [11]. Severe acute
toxicities were more common in patients receiving M-CAVI,
particularly in those with poor renal function [11].
There are five PD-1/PD-L1 inhibitors—atezolizumab,
pembrolizumab, nivolumab, durvalumab, and avelumab—
now approved in the USA for use in patients with advanced
UCwho have progressed during or within 12mo of receiving
platinum-based chemotherapy [12–16]. Atezolizumab, pem-
brolizumab, and nivolumab are also approved for relapsed
UC in Europe [17–19]. The licences for atezolizumab and
pembrolizumab were recently extended to include first-line
treatment in cisplatin-ineligible patients [12,14,18,19]. PD-1/
PD-L1 inhibitors are effective in only a proportion of patients
with advanced UC, but responses appear to be durable for
these patients [20–26]. In clinical trials, treatment was
continued for either a fixed duration or until disease
progression, unacceptable toxicity, or study completion. In
clinical practice, the optimal treatment duration for anti-PD-
1/PD-L1 drugs in UC is unknown, and patients generally
continue to receive these treatments until loss of clinical
benefit or unacceptable toxicity.
Here we summarise current clinical evidence for PD-1/
PD-L1 inhibitors in the treatment of advanced UC.
Importantly, we consider what this evidence means for
real-life clinical practice in terms of selecting patients with
UC for immunotherapy and when, or if, treatment with
these agents can be stopped.
2. Evidence acquisition
A PubMed search of the literaturewas performed for original
research reports using the terms “bladder cancer”, “urothe-
lial carcinoma”, “urothelial cancer”, “transitional cell carci-
noma”, “immunotherapy”, “atezolizumab”, “avelumab”,
“durvalumab”, “nivolumab”, “pembrolizumab”, “checkpoint
inhibitor”, “PD-1”, and “PD-L1”. The search was restricted to
articles in English published since 2007 and limited to fully
published reports of prospective clinical trials. An additional
search was carried out to identify trials of chemotherapy
regimens used in cisplatin-ineligible patients in the first-line
setting for comparison with safety data from immunothera-
py trials. Additional terms for this search included “cisplatin-
ineligible”, “unfit”, “carboplatin”, “first-line”, and “untreat-
ed”. Prospectivemulticentre trials published in the past 10 yr
were included, as well as other relevant peer-reviewed
publications known to the authors.
3. Evidence synthesis
A flowchart of the search strategy is shown in Supplemen-
tary Figure 1. The search identified reports for 12 trials of
PD-1/PD-L1 inhibitors in advanced UC, which are sum-
marised below.
3.1. PD-1/PD-L1 inhibitors in the post-platinum setting
Atezolizumab was granted accelerated approval in the USA
on the basis of results from IMvigor210, a two-cohort,
[(Fig._1)TD$FIG]
Fig. 1 – PD-1/PD-L1 inhibitors prevent the suppression of antitumour T-cell effector functions. The PD-1/PD-L1 interaction is a component of a complex
and incompletely understood mechanism for control of immune surveillance that is corrupted by some tumours. (A) Binding of PD-L1 to PD-1 results
in downstream suppression of normal T-cell effector functions [43]. Tumours expressing PD-L1 use this pathway to evade the antitumour activity of T
cells within the tumour microenvironment and prevent the activation and migration of tumour-infiltrating lymphocytes to the tumour site [43]. (B)
By preventing this suppression, PD-1/PD-L1 inhibitors effectively kick start the immune response against the cancer cells. As PD-L1 binds PD-1 and
B7-1, and PD-1 is bound by PD-L1 or PD-L2, PD-1 and PD-L1 inhibitors have different interactions, which may or may not matter clinically.
MHC = major histocompatibility complex.
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was followed by the confirmatory phase 3 trial IMvigor211,
which involved 931 patients randomly assigned to receive
atezolizumab or the investigators’ choice of vinflunine,
docetaxel, or paclitaxel [27]. IMvigor211 did not meet its
primary endpoint of OS, which was first evaluated in
patients with PD-L1 expression on 5% of immune cells
(IC2/3 population; n = 234) in accordance with the pre-
specified hierarchical testing procedure. In this population,
the median OS was 11.1 and 10.6 mo in the atezolizumab
and chemotherapy arms, respectively (hazard ratio [HR]
0.87, 95% confidence interval [CI] 0.63–1.21; p = 0.41).
Exploratory analysis demonstrated a significant difference
in OS in the intent-to-treat (ITT) population for patients
treated with atezolizumab compared with chemotherapy
(HR 0.85, 95% CI 0.73–0.99; p = 0.038; Table 1) [27,28]. In the
IC2/3 population, ORRs were similar between atezolizumab
and chemotherapy (23.0% vs 21.6%), but the median
duration of response was longer in the atezolizumab arm
(15.9 vs 8.3 mo; HR 0.57, 95% CI 0.26–1.26). Responses to
atezolizumab were durable regardless of PD-L1 status, and
PD-L1 expression appeared to be prognostic rather than
predictive of response [28]. In the ITT population, treat-
ment-related adverse events (AEs) of any grade and of grade
3/4 and AEs that led to treatment discontinuation were
more commonwith chemotherapy than with atezolizumab
(Table 2). AEs of special interest of any grade occurred in 139
(30.3%) and 98 patients (22.1%) in the atezolizumab and
chemotherapy groups, respectively. Grade 3/4 AEs of special
interest occurred in 37 (8.1%) and 13 patients (2.9%),
respectively. Overall, results from IMvigor211 were consis-
tent with those from earlier studies of atezolizumab
(Table 1) [25,29]. The previous phase 2 trial, IMvigor210
(cohort 2), enrolled 310 patients who had experienced
progression after platinum-based therapy. These patients
were treated with atezolizumab, which resulted in an ORR
of 15% (Table 1) [25]. PD-L1 expression on tumour-
infiltrating immune cells was associated with an increased
response to atezolizumab, with an ORR of 26% in the IC2/3
population and 18% for those with expression on 1% of
immune cells (IC1/2/3), similar to that seen in the phase
3 study [27]. Of the 121 patients who were treated beyond
RECIST v1.1-defined disease progression, 20 (16.5%)went on
to experience a reduction in the target lesion of at least 30%
from baseline [25]. Further post hoc analysis of postpro-
gression outcomes in this trial confirmed a prolonged
clinical benefit in patientswho continued treatment beyond
progression [30]. The safety profile of atezolizumab was
similar to that observed in IMvigor211. The incidence of
immune-mediated AEs is summarised in Table 3 [25]. Ex-
ploratory biomarker analyses suggested associations be-
tween the response to atezolizumab treatment and The
Cancer Genome Atlas (TCGA) gene expression subtype,
tumour mutational burden, and CD8 infiltration [25].
The other phase 3 trial of a PD-1/PD-L1 inhibitor
completed in the post-platinum setting in advanced UC
tested the PD-1 inhibitor pembrolizumab [14]. KEYNOTE
045, like IMvigor211, randomised patients (n = 542) to
receive pembrolizumab or the investigators’ choice ofsingle-agent chemotherapy [22]. Median OS was signifi-
cantly better among patients treated with pembrolizumab
compared with those treated with chemotherapy in the ITT
population (Table 1; HR 0.73, 95% CI 0.59–0.91; p = 0.002)
[22]. This benefit was evident regardless of PD-L1 expres-
sion and in all subgroups examined. There was no
significant difference in PFS between treatment groups
(HR 0.98, 95% CI 0.81–1.19; p = 0.42). ORR was significantly
higher in the pembrolizumab than in the chemotherapy
group (p = 0.001), and responses in the pembrolizumab
group were durable (Table 1). Overall, treatment-related
AEs of any grade and grade 3 were more common in the
chemotherapy arm (Table 2). Immune-mediated AEs were
observed in 45 patients (16.9%) in the pembrolizumab arm
(Table 3) and 19 (7.5%) in the chemotherapy arm. These
results support previous observations in the UC cohort of
the KEYNOTE 012 phase 1b study (Table 1) [31].
Nivolumab is a PD-1 inhibitor that was approved for
patients with advanced UC who failed to respond to
previous platinum-based chemotherapy on the basis of
results from the phase 2 CheckMate 275 trial (n = 265;
Table 1) [26]. Favourable ORR outcomes were observed for
all treated patients and across all PD-L1 subgroups when
compared with the historical control of single-drug
chemotherapy [26]. Responses were ongoing at the time
of analysis in 40 of the 52 patients who achieved a response,
including four patients who had stopped nivolumab and
had not received subsequent treatment [26]. Responses to
nivolumab were observed across all predefined patient
subgroups [26]. Seventy patients (26.4%) were treated
beyond disease progression. Of these, 24 (34.3%) went on to
experience a nonconventional clinical benefit [26]. Treat-
ment-related AEs occurred in 174 patients (64.4%), the
majority of which were grade 1/2 [26], and were similar to
those described for atezolizumab and pembrolizumab
(Table 2).Most immune-mediated AEs resolvedwith steroid
treatment (Table 3); however, some endocrine-associated
AEs required ongoing hormone replacement therapy
[26]. Exploratory biomarker analyses suggested that mar-
kers of pre-existing immunity might be associated with a
response to nivolumab [26]. Similar observations were
made in CheckMate 032, an earlier phase 1/2 trial (Table 1)
[32].
Although not yet approved in Europe, the PD-L1 inhibitor
durvalumab has been granted accelerated approval in the
USA for patients with advanced UC who have experienced
progression on platinum-containing chemotherapy. Ap-
proval was based on the results from an ongoing phase 1/2
study that involved 191 patients who had experienced
progression on or within 1 yr of receiving platinum-based
chemotherapy, with the exception of nine treatment-naïve
patients [24]. Patients received durvalumab for up to 1 yr.
Responses were achieved in 34 patients (17.8%) and were
observed in all subgroups examined. Responses appeared
durable, with 26 patients (76.5%) experiencing an ongoing
response at the time of analysis, including six patients who
stopped treatment after completing 12 mo of durvalumab
[24]. ORR was 28% among patients classified as PD-L1-high
(25% of either tumour or immune cells) comparedwith 5%
Table 1 – Clinical trials of PD-1/PD-L1 inhibitors in the postplatinum treatment of advanced urothelial carcinomaa
Trial Treatment
received/median
duration
n Response Median time
to response
Median duration
of response
Median OS,
mo (95% CI)
12-mo OS,
% (95% CI)
Median PFS,
mob (95% CI)
12-mo PFS,
% (95% CI)
ORR, % (95% CI) BR (%)a
NCT01375842 [29];
phase 1 expansion
study; minimum FU
6 wk; PEs, safety and
tolerability
Atezolizumab
15 mg/kg Q3W/
65 d (range 1–259)
65 IHC 2/3:
43 (26–63)
IHC 0/1:
11 (4–26)
IHC 2/3:
CR 7
NRP IHC 2/3: NR
(range 0.1+ to
30.3+ wk)
IHC 0/1: NR
(range 0.1+
to 6.0+ wk)
NRP NRP NRP NRP
IMvigor210 Cohort 2
[25]; single-arm
phase 2; MFU
11.7 mo; PE, ORR
Atezolizumab
1200 mg Q3W/12 wk
(range 0–66)
310 15 (11–19) CR 5
PR 10
SD 19
PD 51
NE 15
2.1 mo
(95% CI 2.0–2.2)
NR 7.9 (6.6–9.3) 36 (30–41) 2.1 (2.1–2.1) NRP
IMvigor211 [27];
randomised phase 3;
MFU 17.8 mo; PE, OS
tested hierarchically
in pre-speciﬁed
populations
Atezolizumab
1200 mg Q3W/
2.8 mo (range 0–24)
467 13 (11–17) CR 3
PR 10
SD 20
PD 52
NE 15
NRP 21.7 mo (95%
CI 13.0–21.7)
8.6 (7.8–9.6) 39.2 (34.8–43.7) 2.1 (2.1–2.2) NRP
Chemotherapy Q3W/
vinﬂunine 2.1 mo
(range 0–15);
paclitaxel 2.1 mo
(range 0–23);
docetaxel 1.6 mo
(range 0–10)
464 13 (11–17) CR 3
PR 10
SD 35
PD 32
NE 19
NRP 7.4 mo (95%
CI 6.1–10.3)
8.0 (7.2–8.6) 32.4 (28.0–36.8) 4.0 (3.4–4.2) NRP
KEYNOTE 012 [31];
multicohort phase
1b; MFU 13 mo; PEs,
safety and ORR
Pembrolizumab
10 mg/kg Q2W/71 d
(range 1–708)
27 26 (11–46) CR 11
PR 15
SD 15
PD 52
NE 7
2 mo (range
2–13)
10 mo
(range 4–22+)
13 (5–20) 50 (29–70) 2 (2–4) 15 (5–31)
KEYNOTE 045 [22];
randomised phase 3;
MFU 14.1 mo; PEs, OS
and PFS
Pembrolizumab
200 mg Q3W/3.5 mo
(range <0.1–20)
Chemotherapy Q3W/
1.5 mo (range
<0.1–14.2)
270
272
21 (16–27)
11 (8–16)
CR 7
PR 14
SD 17
PD 48.5
NE 13
CR 3
PR 8
SD 33.5
PD 33
NE 22
2.1 mo
(range 1.4–6.3)
2.1 mo
(range 1.7–4.9)
NR (range
1.6+ to 15.6+ mo)
4.3 mo (range
1.4+ to 15.4+)
10.3 (8.0–11.8)
7.4 (6.1–8.3)
43.9 (37.8–49.9)
30.7 (25.0–36.7)
2.1 (2.0–2.2)
3.3 (2.3–3.5)
16.8
(12.3–22.0)
6.2 (3.3–10.2)
CheckMate 032 [32];
single-arm phase 1/
2; MFU 15.2 mo; PE,
ORR
Nivolumab 3 mg/kg
Q2W/8.5 doses
(range 1–46)
78 24 (15–35) CR 6
PR 18
SD 28
PD 38
NE 9
1.5 mo
(IQR 1.2–4.1)
9.4 mo
(IQR 5.7–12.5)
9.7 (7.3–16.2) 46 (34–56) 2.8 (1.5–5.9) 21 (12–31)
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Table 1 (Continued )
Trial Treatment
received/median
duration
n Response Median time
to response
Median duration
of response
Median OS,
mo (95% CI)
12-mo OS,
% (95% CI)
Median PFS,
mob (95% CI)
12-mo PFS,
% (95% CI)
ORR, % (95% CI) BR (%)a
CheckMate 275 [26];
single-arm phase 2;
MFU 7.0 mo; PE, ORR
Nivolumab 3 mg/kg
Q2W/NRP
265 20 (15–25) CR 2
PR 17
SD 23
PD 39
NE 18
1.9 mo
(IQR 1.8–2.0)
NR (IQR 7.4 mo–NR) 8.74 (6.05–NR) NRP 2.0 (1.9–2.6) NRP
Study 1108 [24];
single-arm phase 1/
2; MFU 5.8 mo, PEs,
safety and ORR
Durvalumab
10 mg/kg Q2W/
2.8 mo (range
0.4–12.5)
191 18 (13–24) CR 4
PR 14
NE 17
1.4 mo
(range 1.2–7.2)
NR (range 0.9+
to 19.9+ mo)
18.2 (8.1–NE) 55 (44–65) 1.5 (1.4–1.9) 16 (10–23)
JAVELIN Solid Tumor:
initial cohort [33];
expansion cohort
phase 1b; MFU 16.5
mo; PEs, safety and
tolerability
Avelumab 10 mg/kg
Q2W/14.1 wk (IQR
6.0–35.1)
44 18 (8–33) CR 11
PR 7
SD 34
PD 34
NE 14
13.0 wk
(IQR 8.8–38.6)
NR (95% CI
12.1 wk–NE)
13.7 (8.5–NE) 54.3 (37.9–68.1) 11.6 wk (6.1–17.4) 19.1 (8.5–32.8)
at 48 wk
JAVELIN Solid Tumor:
pooled analysis [23];
expansion cohort
phase 1b; MFU 9.9
mo; PE, ORR
Avelumab 10 mg/kg
Q2W
/12.0 wk (IQR
6.0–19.7)
249c 17 (11–24) CR 6
PR 11
SD 23
PD 42
NE 18
11.4 wk
(IQR 5.9–17.4)
NR (95% CI 42.1
wk–NE)
6.5 (4.8–9.5) 53 (45–60)
at 6 mo
6.6 wk (6.1–11.4) 24 (18–31)
at 24 wk
+ = ongoing response at data cutoff; BR = best response; CI = conﬁdence interval; CR = complete response; IHC = immunohistochemistry; IQR = interquartile range; MFU = median follow-up; NE = not estimable; NR = not
reached; NRP = not reported; ORR = objective response rate; OS = overall survival; PD = progressive disease; PE = primary endpoint; PFS = progression-free survival; PR = partial response; Q2W = every 2 wk; Q3W = every 3
wk; SD = stable disease.
a Some percentages do not add up to 100 because of rounding.
b Unless otherwise indicated.
c n = 161 postplatinum patients with >6 mo of FU follow-up included in the efficacy analysis.
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Table 2 – Treatment-related AE data from trials of PD-1/PD-L1 inhibitors in patients with advanced urothelial carcinoma who experienced progression on platinum-based chemotherapy
IMvigor211 [27] KEYNOTE 045 [22] CheckMate 275 [26] Study 1108 [24] JAVELIN Solid
Tumor [23]
Atezolizumab Chemotherapy Pembrolizumab Chemotherapy Nivolumab Durvalumab Avelumab
Patients (n) 459 443 266 255 270 191 249
Any grade AE, n (%) 319 (69.5) 395 (89.2) 162 (60.9) 230 (90.2) 174 (64.4) 116 (60.7) 166 (66.7)
Most common Fatigue: 71 (15.5)
# appetite: 56 (12.2)
Pruritus: 55 (12.0)
Asthenia: 51 (11.1)
Diarrhoea: 50 (10.9)
Constipation: 145
(32.7)
Alopecia: 120 (27.1)
Nausea: 117 (26.4)
Fatigue: 116 (26.2)
Pruritus: 52 (19.5)
Fatigue: 37 (13.9)
Nausea: 29 (10.9)
Diarrhoea: 24 (9.0)
Alopecia: 96 (37.6)
Fatigue: 71 (27.8)
Anaemia: 63 (24.7)
Nausea: 62 (24.3)
Constipation: 52 (20.4)
Fatigue: 45 (16.7)
Pruritus: 25 (9.3)
Diarrhoea: 24 (8.9)
# appetite: 22 (8.1)
Fatigue: 37 (19.4)
# appetite: 18 (9.4)
Diarrhoea: 16 (8.4)
Rash: 14 (7.3)
Infusion-related
reaction: 73 (29.3)
Fatigue: 40 (16.1)
Rash: 37 (14.9)
Diarrhoea: 15 (6.0)
Grade 3/4, n (%) 91 (19.8) 189 (42.7) 36 (13.5)a 122 (47.8)a 48 (17.8) 13 (6.8) 20 (8.0)
Most common Anaemia: 9 (2.0)
Asthenia: 8 (1.7)
Fatigue: 7 (1.5)
Neutropenia: 49 (11.1)
# NC: 26 (5.9)
Febrile neutropenia: 25
(5.6)
Anaemia: 21 (4.7)
Pneumonitis: 5 (1.9)
Colitis: 3 (1.1)
Fatigue: 3 (1.1)
Diarrhoea: 3 (1.1)
Neutropenia: 34 (13.3)
# NC: 31 (12.2)
Anaemia: 20 (7.8)
Fatigue: 11 (4.3)
Fatigue: 5 (1.9)
Diarrhoea: 5 (1.9)
Asthenia: 4 (1.5)
Rash: 3 (1.1)
" AST: 3 (1.6)
" ALT: 2 (1.0)
" GGT: 2 (1)
Hypertension: 2 (1.0)
Fatigue: 4 (1.6)
Asthenia: 2 (0.8)
Elevated lipase: 2
(0.8)
Hypophosphataemia:
2 (0.8)
Serious AE, n (%) 72 (15.7) 110 (24.8) Not reported Not reported Not reported 9 (4.7) 19 (7.6)
AE leading to
discontinuation, n (%)
16 (3.5) 63 (14.2) 15 (5.6) 28 (11.0) 13 (4.8) 3 (1.6) 14 (5.6)
AE leading to death, n (%) 4 (0.9)
General physical health
deterioration;
respiratory failure;
intestinal perforation;
toxic epidermal
necrolysis
9 (2.0)
Cardiorespiratory
arrest; death (2)b;
respiratory tract
infection; sepsis;
pneumonia (2); septic
shock; toxic shock
syndrome
4 (1.5)
Pneumonitis; urinary
tract obstruction;
malignant neoplasm
progression;
unspeciﬁed
4 (1.6)
Sepsis (2); septic
shock; unspeciﬁed
3 (1.1)
Pneumonitis; acute
respiratory failure;
cardiovascular failure
2 (1.0)
Autoimmune hepatitis;
pneumonitis
1 (0.4)
Pneumonitis
AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; GGT = gamma-glutamyltransferase; NC = neutrophil count.
a Grade 3/4 data for KEYNOTE 045 were calculated by subtracting grade 5 data from the data in Table 2 in [22].
b Annotated under general disorders and administration site conditions.
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Table 3 – Immune-mediated adverse events (any grade) reported in at least two patients in clinical trials of PD-1/PD-L1 inhibitors in advanced urothelial carcinoma
Patients, n (%)
Atezolizumab Pembrolizumab Nivolumab Durvalumab Avelumab
IMvigor210 cohort 1
[21] (n = 119)
IMvigor210 cohort 2
[25] (n = 310)
KEYNOTE 052
[20] (n = 370)
KEYNOTE 045
[22] (n = 266)
CheckMate 032
[32] (n = 78)a
CheckMate 275
[26] (n = 270)b
Study 1108
[44] (n = 191)b
JAVELIN Solid Tumor
[23] (n = 249)b
Overall 14 (11.8) 23 (7.4) 63 (17.0) 45 (16.9) – – 22 (11.5) 34 (13.7)
Skin-related – – – – – 47 (17.4) – –
Rash 4 (3.4) 2 (0.6) 7 (9) – 2 (1.0) 12 (4.8)
Severe skin reaction – – – 2 (0.8) – – – –
Endocrine-related – – – – – 39 (14.4) – –
Hypothyroidism 1 (0.8) – 24 (6.5) 17 (6.4) – – 10 (5.2) 9 (3.6)
Hyperthyroidism – – 9 (2.4) 10 (3.8) 3 (4) – 2 (1.0) 2 (0.8)
Thyroiditis – – 2 (0.5) 2 (0.8) – – – –
Hypothyroidism/thyroiditis – – – 7 (9) – – –
Adrenal insufﬁciency – – 5 (1.4) 1 (0.4) 0 – 1 (0.5) –
Type 1 diabetes – – 3 (0.8) – 0 – – –
Diabetic ketoacidosis – – 2 (0.5) – – – – –
Gastrointestinal-related – – – – – 25 (9.3) – –
Diarrhoea 1 (0.8) – – – – 4 (2.1) 1 (0.4)
Colitis 1 (0.8) – 8 (2.2) 6 (2.3) – – 1 (0.5) –
Diarrhoea/colitis – – – – 2 (3) – – –
Pulmonary-related – – – – – 10 (3.7) – –
Pneumonitis – 2 (0.6) 7 (1.9) 11 (4.1) 2 (3) – 1 (0.5) 3 (1.2)
Dyspnoea – 2 (0.6) – – – – – –
Hepatic-related – – – – – 10 (3.7) – –
Hepatitis – – – – 3 (4) – – –
Increased ALT 2 (1.7) 2 (0.6) – – – – – 1 (0.4)
Increased AST 1 (0.8) 2 (0.6) – – – – – 2 (0.8)
Increased blood bilirubin 2 (1.7) – – – – – – –
Renal-related – 0 – – – 3 (1.1) – –
Nephritis – – – 2 (0.8) 1 (1) – – –
Other – – – – – – – –
Rhabdomyolysis 2 (1.7) – – – – – – –
Infusion reaction – – – 2 (0.8) – – – –
– = not reported; ALT = alanine aminotransferase; AST = aspartate aminotransferase.
a Includes only patients who received immune-modulating medication for treatment of the event, with the exception of endocrine events.
b Treatment-related events.
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tumour and immune cells). The incidence of treatment-
related AEs and immune-mediated AEs is summarised in
Tables 2 and 3, respectively [24].
The JAVELIN Solid Tumor study is a phase 1 trial
evaluating avelumab in patients with a range of tumour
types. A pooled analysis of two cohorts of patients with
advanced UC (n = 249) who received at least one dose of
avelumab was recently reported [23]. This included
161 patients with platinum-refractory disease with a
minimum of 6-mo follow-up who were included in the
efficacy analyses [23]. Aftermedian follow-up of 9.9mo, the
response rates to avelumab were comparable to those seen
with other PD-1/PD-L1 inhibitors (Table 1). At data cutoff,
responses were ongoing in 81.4% of patients, including eight
of the nine patients who achieved CR. Responses were seen
in patients with poor prognostic factors, including heavily
pretreated patients and thosewith visceralmetastases. ORR
was 24% among PD-L1-positive patients (5% tumour cells)
versus 13% among PD-L1-low/negative patients. PFS was
also prolonged in patients with higher PD-L1 expression
[23]. These findings support earlier results from the initial
cohort of 44 patients (Table 1) [33]. Treatment-related AEs
occurred at a similar rate as for other PD-1/PD-L1 inhibitors
(Table 2). However, 29% of patients in the JAVELIN Solid
Tumor trial experienced an infusion-related reaction (all
grade 1/2), which may be a higher rate than that observed
with other drugs in the class [23]. AEs that were potentially
immune-mediated occurred in 34 patients (13.7%; Table 3).
3.2. PD-1/PD-L1 inhibitors in the frontline setting in cisplatin-
ineligible patients
Approximately half of patients with advanced UC who are
considered for systemic therapy are deemed unfit for
cisplatin-based chemotherapy because of renal im-
pairment, comorbidities, and/or a poor performance status
[2]. Until recently, these patients would have been offered
carboplatin-based chemotherapy, which has poor efficacy
with regard to OS but reasonable ORRs in this setting, or
best supportive care. Now patients also have the option of
pembrolizumab or atezolizumab. These immunotherapies
were approved for use as first-line treatment in cisplatin-
ineligible patients following results from two multicentre,
single-arm, phase 2 trials in this patient population (Table 4)
[20,21]. It has not yet been established that either of these
options provides a survival advantage over carboplatin-
based chemotherapy or best supportive care in cisplatin-
ineligible patients in randomised head-to-head compar-
isons, although the single-arm phase 2 data for atezolizu-
mab are encouraging, with median OS of almost 16 mo (see
below). Ongoing prospective randomised studies are
addressing this question.
IMvigor210 (cohort 1) included 119 previously untreated
patients with advanced UC who received atezolizumab
[21]. An objective response to atezolizumabwas achieved in
23% of patients, with median OS of 15.9 mo (Table 4). As
seen in the post-platinum setting, responses to atezolizu-
mab were durable, with 19 of 27 responses ongoing at thetime of analysis. In 11 patients who stopped treatment after
achieving CR or PR, six had an ongoing response, four had
progressive disease, and one had died by the data cutoff
date. ORRs in all PD-L1 subgroupswere comparable to those
observed in the overall population, and included a response
rate of 21% in patients negative for PD-L1 expression on
tumour-infiltrating immune cells [21]. Exploratory bio-
marker analyses suggested a potential predictive role for
tumour mutational burden and TCGA molecular subtype in
the response to atezolizumab, in agreementwith findings in
the postplatinum setting [25]. Similarly, the incidence of
treatment-related AEs in the first-line setting was also
comparable to that observed in patients who had previously
experienced progression on platinum-based chemotherapy
(Table 5).
Results from KEYNOTE 052, a phase 2 trial of pembro-
lizumab in cisplatin-ineligible patients, led to approval of
pembrolizumab in the frontline setting in this group.
Response rates to pembrolizumab were similar to those
observed for atezolizumab in this patient population
(Table 4). Responses appeared to be durable, with 83.1%
of responses ongoing at the time of data cutoff. In contrast to
atezolizumab, high PD-L1 expression (10% on both tumour
and immune cells) enriched the response to pembrolizu-
mab, but responses were still seen in those with low PD-L1
expression (<1%). Pembrolizumab exhibited activity re-
gardless of age, performance status, and the presence of
metastases [20]. OS data were considered immature at the
time of publication, as median follow-up for patients in
KEYNOTE 052was 5mo [20]. However, aftermedian follow-
up of 9.5 mo, the median OS was calculated as 11.0 mo (95%
CI 10.0–13.6) [18]. Toxicity data were comparable to those
observed for atezolizumab in the first-line setting (Table 5)
[20].
3.3. What these data mean for clinical practice
In the postplatinum setting there are high-level phase
3 data supporting the use of pembrolizumab in the
treatment of advanced UC [22]. Atezolizumab did not
meet its primaryendpoint in the confirmatory phase 3 trial,
but did induce durable responses with a safety profile
distinct from single-agent chemotherapy [27]. Clinical trial
data for other PD-1/PD-L1 inhibitors suggest that nivolu-
mab, avelumab, and durvalumab can also induce long-
lasting responses in some patients, which has led to
accelerated approval of these drugs in some countries
while confirmatory phase 3 trials are performed [22–
26]. Patients who have been excluded from clinical trials
include those with predominantly non-urothelial histolo-
gy, autoimmune disease, significant organ dysfunction, or
symptomatic brainmetastases, so evidence supporting the
use of immune checkpoint inhibitors in these populations
is lacking. Response rates in clinical trials in the post-
platinum setting range from 13% to 26%, and although this
does not capture patients who achieve stable disease who
still appear to benefit from immunotherapy to some extent
[21], it does suggest that these treatments are not effective
in a substantial proportion of patients [22–26]. There is
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benefit from treatmentwith a PD-1/PD-L1 inhibitor. Unlike
other tumour types [34], PD-L1 expression has not
demonstrated utility as a predictor of response to
immunotherapy in UC. Subgroup analyses of clinical trials
inUChave also failed to identify clinical characteristics that
predict better outcomes for immunotherapy compared
with chemotherapy, or vice versa. Thus, none of the
evidence generated to date is strong enough to support
refusing PD-1/PD-L1 inhibitor treatment on the basis of
such markers. Owing to the clear benefits seen in patients
who do respond to immunotherapy and the lack of better
alternatives, treatmentwith a PD-1/PD-L1 inhibitor should
be considered for all eligible patients who have experi-
enced disease progression on or soon after platinum-based
chemotherapy.
In the frontline setting, single-arm trials have shown that
pembrolizumab and atezolizumab are active in patients
who are not eligible for cisplatin-based treatment
[20,21]. However, there is currently no direct evidence to
indicate that their efficacy is better than existing standards
of care. ORRs are higher for carboplatin-based chemothera-
py than immunotherapy (30–40% vs 23–24%), but median
OS is shorter (8.1–9.3 vs 11.0–15.9 mo) [11,20,21]. To what
extent these differences are due to patient selection is
unclear. In current practice, the decision to opt for one
treatment strategy over the other may come down to
clinical judgement, taking into account factors such as
speed of disease and treatment toxicity. Haematological
toxicities are commonly associated with chemotherapy
regimens (Table 5), particularly affecting those with renal
impairment [11]. Although severe, these AEs are manage-
able and generally resolve quickly. The incidence and
severity of treatment-related AEs are lower with immune
checkpoint inhibitors than with chemotherapy (Table 5).
However, immune-related AEs associated with PD-1/PD-L1
inhibitors can occur across a variety of organs (Table 3) and
may have long-term effects that require prolonged treat-
ment [26]. Management of these toxicities requires early
involvement of the relevant clinical teams and potentially
the use of corticosteroids or hormone replacement thera-
pies [35]. Thus, immunotherapy and chemotherapy offer
different toxicity and efficacy profiles in cisplatin-ineligible
patients in the first-line setting. These issues should be
discussed with patients who are suitable for either
treatment, so that the patient can make an informed
decision. Ideally, such patients should be entered into
ongoing clinical trials to improve the evidence base for
making these decisions. Another consideration in this
decision-making is the lack of published data supporting
the use of chemotherapy after failure of first-line immuno-
therapy, in contrast to the availability of high-level evidence
for the use of immunotherapy after unsuccessful carbopla-
tin-based treatment. The optimal sequencing of these
treatments in this setting, and whether combining immu-
notherapy with carboplatin-based chemotherapy is more
effective than either agent alone remain unclear. Ongoing
clinical trials, such as IMvigor130, KEYNOTE 361, and
DANUBE, should shed some light on this issue [36–38].
Table 5 – Toxicity data from trials of PD-1/PD-L1 inhibitors and chemotherapy as first-line treatment for advanced urothelial carcinoma in
cisplatin-ineligible patientsa
Trial Treatment arm(s) Cisplatin ineligibility criteria, n (%) Safety data, n (%)
IMvigor210 cohort 1 [21]
Phase 2
Atezolizumab
(n = 119)
Renal impairment:b 83 (69.7)
Hearing loss: 17 (14.3)
Peripheral neuropathy: 7 (5.9)
ECOG PS 2: 24 (20.2)
Renal impairment and ECOG PS 2: 8
(6.7)
Any grade TRAEs, 79 (66.4); most common: fatigue,
36 (30.3); diarrhoea, 14 (11.8); pruritus, 13 (10.9)
Grade 3 TRAEs, 20 (16.8); most common: fatigue,
4 (3.4); " ALT 4 (3.4); " AST 3 (2.5)
TRAEs leading to discontinuation, 9 (7.6); TRAEs
leading to death, 1 (0.8)
KEYNOTE 052 [20]
Phase 2
Pembrolizumab
(n = 370)
Renal impairment: 182 (49.2)
ECOG PS 2: 120 (32.4)
Renal impairment and ECOG PS 2: 35
(9.5)
Other:c 33 (8.9)
Any grade TRAEs, 229 (61.9); most common:
fatigue, 62 (16.8); pruritus, 52 (14.1); rash, 36 (9.7)
Grade 3 TRAEs, 58 (28.8); most common: fatigue,
8 (2.2); " ALP, 5 (1.4); colitis, 4 (1.1); muscle
weakness, 4 (1.1)
Serious TRAEs, 36 (9.7); TRAEs leading to
discontinuation, 19 (5.1); TRAEs leading to death, 1
(0.3)
EORTC 30986 [45]
Phase 2
GemCarbo (n = 88) vs M-CAVI
(n = 87)
Renal impairment only: 52 (59.1) vs
51 (58.6)
WHO PS 2 only: 12 (13.6) vs 14 (16.1)
Renal impairment and WHO PS 2: 24
(27.3) vs 22 (25.3)
Serious acute toxicity:d 12 (13.6) vs 20 (23.0)
Mucositis (grade 3): 1 (1.1) vs 5 (5.7)
Thrombocytopenia (grade 4 with bleeding): 3 (3.4)
vs 0
Neutropenic fever (grade 3/4): 5 (5.7) vs 12 (13.8)
Renal toxicity (grade 3/4): 3 (3.4) vs 2 (2.3)
TRAE leading to death: 2 (2.3) vs 4 (4.6)
EORTC 30986 [11]
Phase 2/3
GemCarbo (n = 119)e vs M-CAVI
(n = 119)e
Renal impairment: 66 (55.5) vs 65
(54.6)
WHO PS 2: 21 (17.6) vs 21 (17.6)
Renal impairment and WHO PS 2: 32
(26.9) vs 33 (27.7)
Serious acute toxicity:d 11 (9.3) vs 25 (21.2)
Grade 3/4 toxicities: leukopenia, 53 (44.9) vs 55
(46.6); thrombocytopenia, 57 (48.3) vs 23 (19.5);
neutropenia, 62 (52.5) vs 75 (63.6); infection, 14
(11.9) vs 15 (12.7)
TRAEs leading to death, 2 (1.7) vs 4 (3.4)
Hussain et al. [46]
Phase 1/2
Split-dose GC (n = 32) Renal impairment: 19 (59.4) Grade 3/4 toxicities: thrombocytopenia, 15 (46.9);
neutropenia, 11 (34.4); anaemia, 4 (12.5); nausea, 2
(6.3);
AE leading to death, 3 (9.4)
JASINT1 [47]
Phase 2
Vinﬂunine–gemcitabine (n = 34) vs
vinﬂunine–carboplatin (n = 35)
Renal impairment: 34 (100.0) vs 35
(100.0)
Haematological toxicities of any grade:
neutropenia, 28 (82.4) vs 30 (85.7); anaemia, 33
(97.1) vs 34 (100.0); thrombocytopenia, 24 (70.6)
vs 22 (62.9)
Haematological toxicities grade 3/4: neutropenia,
13 (38.2) vs 23 (65.7); anaemia, 9 (26.5) vs 9 (25.7);
thrombocytopenia, 2 (5.9) vs 7 (20.0)
Nonhaematological toxicities of any grade:
asthenia/fatigue, 20 (58.8) vs 15 (42.9); nausea, 12
(35.3) vs 16 (45.7); constipation, 10 (29.4) vs 14
(40.0)
Nonhaematological toxicities grade 3/4: asthenia/
fatigue, 8 (23.5) vs 7 (20.0); infection, 4 (11.8) vs 1
(2.9); constipation, 1 (2.9) vs 2 (5.7)
No toxic deaths reported
Siefker-Radtke et al. [48]
Phase 2
Gemcitabine, paclitaxel, and
doxorubicin (n = 39)
Renal impairment: 39 (100.0) Haematological toxicities: neutropenia grade 3/4,
13 (33.3); thrombocytopenia grade 3, 6 (15.4);
neutropenic fever, 4 (10.3)
Nonhaematological toxicities grade 3/4: fatigue, 4
(10.3); mucositis, 4 (10.3)
No dose reductions for nephrotoxicity and no
treatment-related deaths
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Table 5 (Continued )
Trial Treatment arm(s) Cisplatin ineligibility criteria, n (%) Safety data, n (%)
GETUG V01 [49]
Phase 2
Gemcitabine (n = 22)f vs
gemcitabine and oxaliplatin
(n = 22)
Renal impairment only: 14 (63.6) vs
12 (54.5)
ECOG PS 2 only: 3 (13.6) vs 4 (18.2)
Renal impairment and ECOG PS 2: 5
(22.7) vs 6 (27.3)
Haematological toxicities: neutropenia grade 3/4:
13 (61.9) vs 7 (31.8); thrombocytopenia grade 3/4:
4 (19.0) vs 5 (22.7); anaemia grade 2/3: 20 (95.2) vs
18 (81.8)
Nonhaematological toxicities: nausea grade 2/3: 4
(19.0) vs 10 (45.5); vomiting grade 2/3: 2 (9.5) vs 4
(18.2); diarrhoea grade 1/2: 8 (38.1) vs 9 (40.9);
mucositis grade 1/2: 4 (19.0) vs 4 (18.2); peripheral
neuropathy grade 1–3: 1 (4.8) vs 15 (68.2);
asthenia any grade: 20 (95.2) vs 19 (86.4)
TRAE leading to discontinuation: 1 (4.8) vs 2 (9.1)
TRAE leading to death: 0 vs 1 (4.5)
Calabro et al. [50]
Phase 2
Gemcitabine and paclitaxel (n = 54) WHO PS 2: 7 (13.0)
Some patients had compromised
renal function (median creatine
clearance was 62 ml/min, range 41–
112)
Haematological toxicities grade 3/4: neutropenia,
10 (18.5); anaemia, 6 (11.1); thrombocytopenia, 3
(5.6), leukopenia, 3 (5.6)
Nonhaematological toxicities grade 3/4:
neurotoxicity, 6 (11.1); diarrhoea 4 (7.4)
AE = adverse event; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for
Adverse Events; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organisation for Research and Treatment of Cancer; GemCarbo = gemcitabine
and carboplatin; M-CAVI = methotrexate, carboplatin, and vinblastine; PS = performance status; TRAE = treatment-related AE; WHO =World Health
Organisation.
a Defined as a patient meeting at least one of the following criteria: WHO or ECOG PS of 2, or Karnofsky PS of 60–70%; creatinine clearance <60 ml/min;
CTCAE grade 2 hearing loss; CTCAE grade 2 peripheral neuropathy; or New York Heart Association class III heart failure [10].
b Defined as glomerular filtration rate or creatine clearance >30 to <60 ml/min.
c Includes New York Heart Association class III heart failure, grade 2 peripheral neuropathy, and grade 2 hearing loss.
d Defined as the occurrence of any of the following events, either directly or at least possibly related to treatment administration: mucositis grade 3 or 4,
thrombocytopenia grade 4 associated with bleeding, neutropenic fever grade 3 or 4, renal toxicity grade 3 or 4, and death.
e n = 118 in the safety population.
f n = 21 in the safety population.
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immunotherapy in UC is whether treatment can be safely
stopped without impacting clinical outcomes. Most trials of
PD-1/PD-L1 inhibitors in advanced UC to date have
continued treatment until disease progression, unaccept-
able toxicity, or study completion, and there is a lack of
clinical evidence and follow-up data on the optimal
treatment duration. Ongoing responses were observed in
study 1108, in which patients stopped durvalumab after
completing 12 mo of treatment [24], and in other trials in
patients who discontinued immunotherapy after achieving
a response [21,22,26]. These reports are anecdotal, and it
remains unclear whether this observation can be extrapo-
lated more widely; however, there have been similar
observations for other tumour types [39,40]. Only one
randomised trial has evaluated the duration of treatment
with a PD-1/PD-L1 inhibitor. CheckMate 153 is an ongoing
phase 3/4 trial in non–small cell lung cancer that random-
ised 220 patients who had been treated with nivolumab for
1 yr to either treatment continuation or cessation, regard-
less of response [41]. Nivolumab continuation significantly
improved PFS comparedwith treatment cessation (HR 0.42,
95% CI 0.25–0.71). Almost half of the patients (43/87) with a
response or stable disease at randomisation developed
progressive disease after discontinuing nivolumab; OS data
are awaited [41]. Owing to the lack of clinical data for UC
and conflicting evidence for other tumours, it is notcurrently possible to saywhether stopping immunotherapy
in advanced UC either after a set duration or once a response
has been achieved is an appropriate treatment approach. In
patients with stable disease who are otherwise well, there
may be a benefit in continuing treatment with PD-1/PD-L1
inhibitors, as late responses have been reported in UC
clinical trials [21,22]. Two patients in IMvigor210 (cohort 1)
and three patients in KEYNOTE 045 achieved responses
6 mo after starting immunotherapy treatment [21,22]. The
current strategy of treating patients until loss of clinical
benefit appears to be the most appropriate course of action
in the first-line and post-platinum settings. However, the
definition of “clinical benefit” is not clear. In the second-line
setting, if a patient exhibits minor disease progression, but
is not deteriorating and has no organ dysfunction, it would
be tempting to continue treatment to the next assessment
point. This approach is supported by data from clinical trials
that show a nonconventional benefit in some patients who
have been treated beyond progression [25,26,32]. However,
if a patient has more significant disease progression,
treatment with PD-1/PD-L1 inhibitors should be stopped.
In the first-line setting, stopping criteria for immunothera-
pies should perhaps be stricter due to the availability of
alternative subsequent treatments. Although some of the
studies described in this review have investigated treat-
ment beyond progression as a surrogate for pseudopro-
gression, no studies have focused on this phenomenon in UC
E U RO P E AN URO L OGY ONCO L OGY 1 ( 2 018 ) 4 8 6 – 5 0 0498and it remains poorly characterised. Thus, owing to the
uncertainty around such progression kinetics, patients who
develop clinically significant disease on first-line immuno-
therapy or experience a deterioration in performance status
or major organ involvement should be switched to
chemotherapy without delay.4. Conclusions
PD-1/PD-L1 inhibitors represent an important advance in
the treatment of advanced UC and significantly improve
prognosis for some patients. A number of key questions
remain. There is no definitive evidence that anti-PD-1/PD-
L1 drugs offer a superior treatment option in the first-line
setting in cisplatin-ineligible patients compared with
current standards of care. It is uncertain when or if
treatment can be stopped without impacting any clinical
benefit achieved, and there are no biomarkers that identify
patients who will benefit from these drugs. In addition,
owing to a lack of head-to-head data, the choice of which
PD-1/PD-L1 inhibitor to use first, or whether there is a
difference in efficacy between anti-PD-1 and anti-PD-L1
drugs, remains uncertain. However, this is a relatively new
research field and it is developing rapidly. Ongoing trials are
investigating the use of PD-1/PD-L1 inhibitors as adjuvant
and maintenance therapy, in earlier disease stages, and in
combination with chemotherapy and/or other immune
checkpoint inhibitors, such as the CTLA-4 inhibitors
ipilimumab and tremelimumab, or targeted therapies
[42]. As these clinical data mature, UC patient populations
eligible for immunotherapy treatment may broaden. In the
metastatic setting, novel next-generation immunothera-
pies, such as indoleamine 2,3-dioxygenase inhibitors, are in
development, which could further expand the treatment
landscape for this difficult-to-treat cancer.
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